Trial Profile
A long-term prospective cohort study on the natural course and effect of intervention in patients with hepatitis C virus infection
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 25 Aug 2020
Price :
$35
*
At a glance
- Drugs Asunaprevir (Primary) ; Daclatasvir (Primary)
- Indications Hepatitis C
- Focus Adverse reactions
- 23 Aug 2020 Planned End Date changed from 1 Mar 2010 to 31 Mar 2025.
- 01 May 2008 New trial record.